Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)
NCT ID: NCT02418481
Last Updated: 2016-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
40 participants
INTERVENTIONAL
2015-04-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficiency of γδ T Cell Against Breast Cancer
NCT03183206
Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer
NCT02844335
Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients
NCT04320979
Bioinformation Therapy for Breast Cancer
NCT03240224
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
NCT06375798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
DC-CIK cells will be used against tumor cells.
DC-CIK
DC-CIK cells will be used against tumor cells.
Group B
γδ T cells will be used against tumor cells.
γδ T Cell
γδ T cells will be used against breast tumor.
Group C
Combination of γδ T cells/ DC-CIK be used against tumor cells.
Combination
γδ T/DC-CIK cells will be used against breast tumor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DC-CIK
DC-CIK cells will be used against tumor cells.
γδ T Cell
γδ T cells will be used against breast tumor.
Combination
γδ T/DC-CIK cells will be used against breast tumor.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Karnofsky performance status \>50
3. Diagnosis with breast tumors based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
5. Will receive cryosurgery, gd Tcells/ DC-CIK.
6. Life expectancy: Greater than 3 months
7. Ability to understand the study protocol and a willingness to sign a written informed consent document
Exclusion Criteria
2. History of coagulation disorders or anemia
3. Patients with heart disease and diabetes
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinan University Guangzhou
OTHER
Fuda Cancer Hospital, Guangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Gd T cell
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.